Background A prognostic model was developed and validated using cancer registry data. This underpins an online decision support tool, informing primary treatment choice for women aged 70 years or older with hormone receptor‐positive early breast cancer. Methods Data from women diagnosed between 2002 and 2010 in the English Northern and Yorkshire and West Midlands regions were used to develop the model. Primary treatment options of surgery with adjuvant endocrine therapy or primary endocrine therapy were compared. Models predicting the hazard of breast cancer‐specific mortality and hazard of other‐cause mortality were combined to derive survival probabilities. The model was validated externally using data from the Eastern Cancer Reg...
BACKGROUND: Older women with breast cancer have poorer relative survival outcomes, but whether achie...
Background: Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is i...
Background Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units...
Background A prognostic model was developed and validated using cancer registry data. This underpin...
Introduction: While breast cancer outcomes are improving steadily in younger women due to advances i...
Background: Age-related breast cancer treatment variance is widespread with many older women having ...
This is the final published version. Available from Springer Nature via the DOI in this record.BACKG...
Background: In breast cancer management, age-related practice variation is widespread, with older wo...
BACKGROUND: Breast cancer is the most common cancer in younger women (aged ⩽40 years) in the United ...
Introduction While breast cancer outcomes are improving steadily in younger women due to advances in...
Background: Primary endocrine therapy (PET) is used as an alternative to surgery in up to 40% of UK ...
BACKGROUND PREDICT is a breast cancer prognostic and treatment benefit model implemented online. ...
Background: Primary endocrine therapy is used as an alternative to surgery in up to 40 per cent of w...
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is...
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is i...
BACKGROUND: Older women with breast cancer have poorer relative survival outcomes, but whether achie...
Background: Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is i...
Background Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units...
Background A prognostic model was developed and validated using cancer registry data. This underpin...
Introduction: While breast cancer outcomes are improving steadily in younger women due to advances i...
Background: Age-related breast cancer treatment variance is widespread with many older women having ...
This is the final published version. Available from Springer Nature via the DOI in this record.BACKG...
Background: In breast cancer management, age-related practice variation is widespread, with older wo...
BACKGROUND: Breast cancer is the most common cancer in younger women (aged ⩽40 years) in the United ...
Introduction While breast cancer outcomes are improving steadily in younger women due to advances in...
Background: Primary endocrine therapy (PET) is used as an alternative to surgery in up to 40% of UK ...
BACKGROUND PREDICT is a breast cancer prognostic and treatment benefit model implemented online. ...
Background: Primary endocrine therapy is used as an alternative to surgery in up to 40 per cent of w...
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is...
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is i...
BACKGROUND: Older women with breast cancer have poorer relative survival outcomes, but whether achie...
Background: Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is i...
Background Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units...